NCT02064985 - Ticagrelor China Pharmacokinetic/Pharmacodynamic Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions

Stable Coronary Heart Disease (CHD)

Interventions

DRUG

"Inhibition of Platelet Aggregation by Brilinta(Ticagrelor)"

To determine the Inhibition of Platelet Aggregation (IPA) profiles of single and multiple doses of ticagrelor 45, 60, and 90 mg in Chinese patients with stable coronary heart disease (CHD) on chronic low dose ASA (75-100mg daily).

Trial Locations (1)

Unknown

Research Site, Beijing